]i by thrombin and blocked potentiation of AA release by B 2R agonists. Because either a nonselective inhibitor (isotetrandrine) of phospholipase A 2 (PLA2) or a Ca 2ϩ -dependent PLA2 inhibitor abolished potentiation of AA release by thrombin, while a Ca 2ϩ -independent PLA2 inhibitor did not, we concluded that the mechanism involves Ca 2ϩ -dependent PLA 2 activation. Both thrombin and TRAP modified activation and phosphorylation of the B 2R induced by BK. In lower concentrations they enhanced it, while higher concentrations inhibited phosphorylation and diminished B 2R activation. Protection of the NH2-terminal Ser 1 -Phe 2 bond of TRAP by an aminopeptidase inhibitor made this peptide much more active than the unprotected agonist. Thus PAR1 activation enhances AA release by B 2R agonists through signal transduction pathway.
]i). Thrombin cleaves the protease-activated-receptor-1 (PAR1) that couples G␣ i, G␣q, and G␣12/13 proteins. In Chinese hamster ovary cells stably transfected with human B 2R, thrombin liberated little AA, but it significantly potentiated AA release by B 2R agonists. We explored mechanisms of cooperativity between constitutively expressed PAR1 and B 2R. We also examined human endothelial cells expressing both Rs constitutively. The PAR1 agonist hexapeptide (TRAP) was as effective as thrombin. Inhibitors of components of G␣ i, G␣q, and G␣12/13 signaling pathways, and a protein kinase C (PKC)-␣ inhibitor, Gö-6976, blocked potentiation, while phorbol, an activator, enhanced it. Several inhibitors, including a RhoA kinase inhibitor, a [Ca 2ϩ ]i antagonist, and an inositol-(1,3,4)-trisphosphate R antagonist, reduced mobilization of [Ca 2ϩ ]i by thrombin and blocked potentiation of AA release by B 2R agonists. Because either a nonselective inhibitor (isotetrandrine) of phospholipase A 2 (PLA2) or a Ca 2ϩ -dependent PLA2 inhibitor abolished potentiation of AA release by thrombin, while a Ca 2ϩ -independent PLA2 inhibitor did not, we concluded that the mechanism involves Ca 2ϩ -dependent PLA 2 activation. Both thrombin and TRAP modified activation and phosphorylation of the B 2R induced by BK. In lower concentrations they enhanced it, while higher concentrations inhibited phosphorylation and diminished B 2R activation. Protection of the NH2-terminal Ser 1 -Phe 2 bond of TRAP by an aminopeptidase inhibitor made this peptide much more active than the unprotected agonist. Thus PAR1 activation enhances AA release by B 2R agonists through signal transduction pathway.
protease-activated-receptor-1; thrombin receptor activator peptide; protein kinases; potentiation; calcium; kallikrein THROMBIN, the potent physiological activator of platelet aggregation, is a major factor in myocardial infarction and other thrombotic processes (15, 22, 32) . In addition to promoting coagulation, thrombin plays a central role in the cellular response to injury or inflammation and wound repair. Thrombin initiates many of these complex cellular events by cleaving the Arg 41 -Ser 42 bond of the protease-activated receptor-1 (PAR1) to expose a new NH 2 terminus. This terminus then acts as a tethered ligand (13, 38) and activates PAR1. Various guanine nucleotide-binding (G) protein ␣-subunits can then couple with PAR1. When coupled to G␣ q protein, PAR1 generates diacylglycerol (DAG) and inositol- (1, 4, 5) trisphosphate (IP 3 ), which in turn binds to IP 3 receptors (Rs) on the endoplasmic reticulum to trigger intracellular calcium concentration [Ca 2ϩ ] i release. Interaction of IP 3 R with transient R potential channel 1 (TRPC1) is required to activate store depletion-induced Ca 2ϩ entry (21, 27, 31) . In addition to G␣ q , the stimulated PAR1 couples G␣ i/0 (14, 25, 37) and G␣ 12/13 proteins (12, 17, 27) . Activation of the G␣ i/o protein leads to release of the prostaglandin precursor arachidonic acid (AA).
Activation of B 2 Rs for bradykinin (BK) can cause among others hypotension, bronchoconstriction, pain, or inflammation (3, 16) and releases vascular mediators such as NO, or prostaglandins, and others (3, 8 -11) . The PAR1-4 group of thrombin and trypsin Rs, as their name indicates, were thought to be unique protease-activated Rs. However, we showed that the human BK B 2 R can be activated by certain proteases as well (20) . Kallikreins and some other human or bacterial serine proteases, including cathepsin G or endoarginase C, can activate B 2 BK Rs directly (19, 20) . Furthermore, activation of the ubiquitous B 2 R by BK or proteolytic enzymes (20) recruits both G␣ i and G␣ q proteins, as indicated by the release of AA and elevation of [Ca 2ϩ ] i (18, 26) . Burch and colleagues (5) (6) (7) found that BK and thrombin synergized prostaglandin synthesis in fibroblasts, and after prolonged stimulation, thrombin amplified responses to BK. After we discovered that kallikrein and other proteases directly activate the BK B 2 Rs (19, 20) , we used cultured cells to determine if thrombin would enhance AA release by kallikrein via B 2 R and if PAR1 activation potentiates kallikrein via signal transduction pathways. We established that the two proteases acted on a single R, either PAR1 or B 2 , because we obtained the same results with peptide agonists specific for the individual Rs. We used inhibitors of the major factors in signal transduction to point out the steps in the potentiation process.
MATERIALS AND METHODS
Chinese hamster ovary (CHO) cells were purchased from American Type Culture Collection (Rockville, MD). Human pulmonary artery endothelial (HPAE) cells were obtained from Clonetics (Walkersville, MD). The cDNA encoding the human BK B 2R was donated by Dr. K. Jarnigan, Syntex (Palo Alto, CA), and the human regulator of G protein signaling type 10 (RGS10) cDNA was from the University of Missouri-Rolla (Rolla, MO). Mammalian expression vectors pcDNA3 were from Invitrogen (San Diego, CA); lipofectin and geneticin (G418) were from GIBCO-BRL (Gaithersburg, MD). [5, 6, 8, 9, 11, 12, 14, Gö-6976, Y-27632, H-89  dihydrochloride, 2-aminoethoxydiphenyl borate (2-APB) , and 8-(N,N-diethylamino)octoyl-3,4,5-trimethoxybenzoate (TMB-8) were from Calbiochem (La Jolla, CA). Human thrombin and human plasma kallikrein were from Enzyme Research Lab (South Bend, IN), BK, porcine pancreatic kallikrein, thermolysin, trypsin, genistein, culture media, penicillin, phorbol-12-myristate 13-acetate (PMA), thrombin R activator peptide (TRAP) and scrambled TRAP (scTRAP), amastatin, and other peptides and chemicals were purchased from Sigma Chemical (St. Louis, MO). HOE-140 was a gift from Dr. B. A. Schölkens, Novartis (Frankfurt, Germany). The Pro-Q diamond phosphoprotein gel stain kit was from Molecular Probes (Eugene, OR).
Cell culture and transfection. CHO cells were grown in Ham's F-12 culture medium supplemented with L-glutamine, penicillin-streptomycin, HEPES buffer, and 10% fetal bovine serum (FBS). One day before transfection, cells were seeded into 60-mm dishes at 30 -40% confluence. The human B 2R and human B2R COOH terminally tagged with the GFP (B 2-GFPct) were inserted into a pCDNA3 vector, and CHO cells were transfected with human BK B2R (CHO/B2), the B2-GFPct (CHO/B2-GFPct), or cotransfected with human BK B2R and RGS10 (CHO/B2 ϩ RGS10) using lipofectin. After 2 h incubation at 37°C, cells were thoroughly washed with DMEM or Ham's F-12 medium, and 2 ml of the same medium containing geneticin (G418) was added to start the selection of stably B2 or tagged B2R-transfected cells. Blasticidin was added to select the RGS10 cotransfected cells. Different clones were selected and propagated using cloning rings. HPAE cells, which constitutively express BK B2Rs, were grown to confluence (4 -6 passages).
[ 3 H]BK saturation binding assay. To select the transfected clone with the highest expression of B2 or B2-GFPct Rs and to quantitate the effect of thrombin on BK binding to its R, we used a [ 3 H]BK saturation binding assay (20) . We found that both human BK B2 and B2-GFPct were expressed on CHO plasma membrane; we estimated the B2R to be 5.8 ϫ 10 4 per cell and the B2-GFPct to be 1. (19) . The experiments were carried out routinely in triplicate.
Thrombin and kallikrein assay. A putative direct effect of TRAP on human plasma kallikrein activity and inactivation of thrombin by diisopropyl fluorophosphate (DFP) were followed fluorometrically by measuring cleavage of D-Val-Leu-Arg-AMC substrate by the two enzymes (1, 36) . Plasma kallikrein (100 nM) was preincubated with increasing concentrations of TRAP from 1 M to 300 M for 15 min. Fifty microliters of kallikrein solution were then mixed with 445 l of 0.1 M Tris ⅐ HCl (pH 8.0). Addition of 5 l of AMC substrate to final concentration of 0.1 mM initiated the reaction. The liberated fluorogenic coumarin derivative was measured in a spectrofluorometer with excitation at 380 nm and emission at 460 nm wavelength; the increase in fluorescence was monitored with a recording spectrofluorometer. We used thrombin irreversibly inhibited by DFP as an additional control.
Human BK B2 immunoprecipitation and phosphorylation. CHO/ B2-GFPct cultures in six-well culture dishes were treated with 1 M BK in the presence or absence of increasing concentrations of thrombin (3 nM-1 M) for 30 min at 37°C. Cells were washed with ice-cold PBS and lysed with 0.4 ml 0.5% deoxycholate (DOC) buffer (pH 7.5) containing 1% NP-40, 0.1% SDS, 1 mM PMSF, 50 mM Tris, 150 mM NaCl, and 10 l protease inhibitor mixture. After being shaken for 10 min at 4°C, the lysates were sonicated and then centrifuged at 16,000 g for 15 min at 4°C. Supernatants were collected and diluted with 390 l of 50 mM Tris buffer (pH 7.5) containing 150 mM NaCl and protease inhibitors. Samples were then incubated with 1 g rabbit anti-GFP antibody overnight at 4°C. B 2-GFPct R immune complexes were precipitated with protein A-Sepharose beads (Sigma) at 4°C for 2 h. The beads were then washed five times with lysis buffer, and the precipitated proteins were eluted by boiling the beads in sample buffer [80 mM Tris (pH 6.8), 3% SDS, 15% glycerol, 0.01% bromophenol blue, 5% DTT]. Proteins were then separated on a 4 -20 % gradient SDS-PAGE gel. The phosphorylated R was selectively stained with a Pro-Q diamond phosphoprotein gel stain kit, and its 555/580 nm excitation/emission maxima were detected with a visible-light-scanning instrument (Molecular Imager FX Pro Plus, Bio-Rad). Density of the band was quantified using Labworks software, and data were expressed as the ratio of phosphorylated protein density/total protein density.
Statistical analysis. Means and SEs were calculated for all experiments, and statistical significance of differences between means was tested by a paired t-test (Microsoft Excel).
RESULTS

Thrombin enhances [ 3 H]AA release by BK B 2 R agonists. BK or kallikrein released [
3 H]AA from labeled CHO cells that were stably transfected to express human B 2 R (CHO/B 2 ). Although these cells express thrombin PAR1 constitutively, direct activation of PAR1 by 10 nM thrombin for 30 min at 37°C released relatively little labeled AA. If the amount released spontaneously was taken as baseline to equal 1.0, the value for AA was 1.76 Ϯ 0.4-fold over the baseline. Figure 1A shows that the amount of AA released by thrombin was unaffected by 0.5 M HOE-140, an inhibitor of the BK B 2 R. However, when thrombin activated PAR1 first, subsequent stimulation of B 2 R with porcine pancreatic kallikrein nearly doubled [ 3 H]AA release from 6.4 Ϯ 1.5 to 12.6 Ϯ 2 (relative units). Similar results were obtained with human plasma kallikrein (5.9 Ϯ 0.8 to 11.0 Ϯ 0.7) and BK (6.3 Ϯ 1.7 to 11.8 Ϯ 2.6), where thrombin-activated cells reacted to the agonists with a significant increase in release of AA. HOE-140 (0.5 M) completely blocked the effects of thrombin receptor activation. We consistently recorded thrombin potentiation of B 2 agonists in numerous experiments: n ϭ 21 for BK (1 nM) and n ϭ 17 for tissue kallikrein (1-10 nM). HPAE cells that constitutively express both receptors confirmed positive cooperativity (P Ͻ 0.01) between PAR1 and BK B 2 Rs (Fig. 1A , right). Human thrombin (10 nM) increased basal release of AA by endothelial cells slightly (1.4 Ϯ 0.1) but also potentiated the effect of BK and plasma kallikrein on the BK B 2 R significantly.
The synthetic thrombin R activating peptide SFLLRN (TRAP) is composed of the first six amino acids of the new NH 2 -terminal tethered ligand that is revealed when thrombin cleaves PAR1. This peptide functions as a PAR1 agonist that activates the R independently of thrombin and proteolysis (12, 38) . TRAP was used as a control for two reasons: it is specific for the PAR1 and it ensures that enhanced B 2 agonist activity results from PAR1 activation, not from thrombin acting on B 2 R (Fig. 1B) (Fig. 1B, right) . As an additional control, thrombin inhibited by 1 mM DFP failed to activate PAR1 and did not modify [ 3 H]AA release by B 2 R agonists. Together these data show that activation of the thrombin PAR1 leads to a positive cooperativity with BK R agonists, resulting in increased receptor-mediated activities.
We did additional experiments with wild-type (WT) CHO cells that have native PAR1 Rs but lack the B 2 Rs. Figure 1C shows calphostin C (100 nM), or a specific inhibitor of PKC␣, Gö-6976 (100 nM) (30) . PKC is not essential for regulation of the B 2 R activity (4), and calphostin C and Gö-6976 did not inhibit AA release by either kallikrein or BK significantly (Fig.  2) . Addition of either calphostin C or Gö-6976 inhibited thrombin potentiation without significantly affecting basal B 2 R activity because it was only slightly less than in untreated cells (Fig. 2A) . Thrombin-potentiated AA release by BK was significantly reduced by calphostin C (7.3 Ϯ 0.9) and Gö-6976 (9.4 Ϯ 1.1) compared with control cells (15.9 Ϯ 1.4) . The thrombin-enhanced response to kallikrein was similarly blocked by calphostin C (4.1 Ϯ 0.3) or Gö-6976 (6.1 Ϯ 0.9) vs. control (10.2 Ϯ 1.1) (Fig. 2B) . Gö-6976 also inhibited the potentiation by TRAP (30 M (Fig. 2) .
Because different signaling pathways resulting from PAR1 activation might be involved in enhancement of the BK B 2 R agonists, we applied additional inhibitors of serine/threonine kinases: a PKG inhibitor, RQIKIWFQNRRMKWKKLRKK-KKH (0.5 M); a PKA inhibitor, H-89 dihydrochloride (0.5 M); an IP 3 kinase inhibitor, wortmannin (0.5 M); and a tyrosine kinase inhibitor, genistein (100 M). None of these agents significantly modified the thrombin potentiation of BK on the B 2 R ( Table 1 ), indicating that it does not require PKG, PKA, IP 3 kinase, or tyrosine kinase. Methyl-␤-cyclodextrin (MCD) can be used to deplete cholesterol from cell membranes and lipid rafts. Because pretreatment of CHO/B 2 cells with 5 mM of MCD for 30 min at 37°C had no effect, it is highly unlikely that thrombin potentiates B 2 R by heterodimerization with PAR1 (Table 1) .
Role of G␣ 12/13 ] i mobilization (Fig. 3A) and the thrombin-induced potentiation of B 2 agonists (4.7 Ϯ 0.6 compared with 9.9 Ϯ 0.8) (Fig. 3B) TMB-8 (7 Ϯ 0.6 compared with 9.9 Ϯ 0.8), a weaker inhibitor of Ca 2ϩ flux (Fig. 3A) . PAR1 agonists can activate other heterotrimeric G proteins, the G␣ i (14, 25, 37) and the G␣ 12/13 (13, 17, 27 ) that initiate cascading downstream processes. The released ␣-subunit of G 12/13 activates P115 Rho guanine nucleotide exchange factor (p115RhoGEF) and thereby also Rho. To determine whether thrombin potentiates BK effects through the G␣ 12/13 pathway as well, we pretreated CHO/B 2 cells for 30 min with 10 M Y-27632, a Rho kinase inhibitor. This inhibitor decreased extracellular Ca 2ϩ entry into thrombinactivated cells (Fig. 3A) and consequently lessened the potentiation of B 2 agonist (6.8 Ϯ 0.7 vs. untreated cells 9.95 Ϯ 0.8). It follows that the mechanism of potentiation at the B 2 R requires Rho acting via IP 3 R to induce [Ca 2ϩ ] i release and activate the subsequent signaling cascade. Based on our experiments with inhibitors, thrombin appears to potentiate plasma kallikrein differently than BK. Even though 2-APB completely blocked the thrombin-induced potentiation of kallikrein just as for BK, neither TMB-8 nor the RhoA kinase blocker Y-27632 blocked it (Fig. 3C) . These data thus suggest that influencing the R of IP 3 is a focal point of interaction between the B 2 R and PAR1 signaling pathway. Additional experiments indicated that kallikrein and BK regulate [Ca 2ϩ ] i mobilization through different mechanisms (D. Biyashev, unpublished observations).
Thrombin enhances cytosolic PLA 2 activation. Among the different isoforms of PLA 2 , cPLA 2 is a major factor for receptor-regulated release of AA from membrane phospholipids (24) . The activity of cPLA 2 is Ca 2ϩ dependent, and increased [Ca 2ϩ ] i triggers translocation from the cytosol to plasma membranes (34, 35) to enhance its activity. Because the thrombin potentiation effect requires mobilization of [Ca 2ϩ ] i , we investigated the role of cPLA 2 . We preincubated CHO/B 2 cells for 30 min with 20 M of isotetrandrine, a nonselective inhibitor that blocks both Ca 2ϩ -dependent and Ca 2ϩ -independent PLA 2 s. When both Ca 2ϩ -dependent and Ca 2ϩ -independent PLA 2 s were inhibited, basal release of [ 3 H]AA by 1 nM BK or by 10 nM plasma kallikrein was blunted (2.5 Ϯ 0.1 vs. 5.9 Ϯ 0.3 and 3.9 Ϯ 0.5 vs. 7.4 Ϯ 0.9), as was potentiation of these agonists by thrombin. A more specific inhibitor of cPLA 2 (20 nM; see MATERIALS AND METHODS) similarly reduced the effects of B 2 R agonists or plasma kallikrein on untreated cells as well as their potentiation by thrombin. In cells where cPLA 2 was inhibited, release of AA fell to approximately one-half that in uninhibited cells. We used BEL, a specific Ca 2ϩ -independent PLA 2 (iPLA 2 ) inhibitor, as a control. Figure 4 shows that BEL (20 M) after 30 min preequilibration inhibited the release of [ 3 H]AA by BK by 32% (4.0 Ϯ 0.5 vs. 5.9 Ϯ 0.3) but not that of plasma kallikrein. However, the relative potentiation by thrombin of either B 2 R agonist was not abolished by BEL. Even though the release of AA by BK in the presence of thrombin decreased, the ratio of [ 3 H]AA released by BK in presence of thrombin (7.9 Ϯ 0.7) over that released in absence of thrombin (4.0 Ϯ 0.5) was similar to the ratio in control cells (9.9 Ϯ 0.8 over 5.9 Ϯ 0.3) (Fig. 4) .
Effect of transfected G␣ i negative regulator. We repeated our thrombin potentiation experiments in CHO/B 2 cells that were cotransfected with a regulator of G protein signaling type 10 (RGS10), which negatively modulates G␣ i/o signaling on Rs activation. Figure 4 shows that expression of RGS10 completely blocked B 2 R agonists, even in the presence of thrombin. RGS10 serves as a GTPase-activating protein for G␣ i/o , but it may also regulate the G␣ q subunit (33 results from increased concentrations of PAR1 agonists. Thrombin potentiated either 1 M or 1 nM BK, but the response was more prominent at the lower BK concentration (Fig. 5A) . Figure 5B shows the precipitation of B 2 R with antibodies to GFP in CHO/B 2 -GFP-transfected cells. CHO/B 2 -GFPct cells were incubated for 30 min with 1 M BK (37°C), and increasing concentrations of thrombin were added. We established that the GFP tag attached to the COOH terminus of the B 2 R affected neither release AA nor mobilization of [Ca 2ϩ ] i (19) . Furthermore, this manipulation did not influence potentiation by thrombin (data not shown). The phosphorylated R was quantified and normalized to the total B 2 protein level using the ratio of phosphorylated protein density/total protein density (Fig. 5B) . The increased basal phosphorylation of the receptor after BK challenge (4.3 Ϯ 0.5-fold) was taken as 100%. Figure 5B shows how B 2 R phosphorylation changed with increasing amounts of thrombin. In the absence of added BK, thrombin did not phosphorylate the BK B 2 R (data not shown), but it enhanced BK-induced phosphorylation of B 2 -GFPct R in a concentration-dependent manner, reaching a maximum of 166% at 30 nM. Higher concentrations of thrombin decreased it. The phosphorylation of B 2 R that thrombin augmented was inhibited in cells pretreated with either 75 M of 2-APB or 100 nM of Gö-6976 (Fig. 5B) .
Similarly to thrombin, TRAP potentiated either 1 nM or 1 M BK on CHO/B 2 -transfected cells. [ 3 H]AA was released in a concentration-dependent manner with maximum at 10 -30 nM of peptide. BK alone increased the basal level of phosphorylation; this increase was taken as 100%, and data from additional treatments are expressed relative to this (Fig. 6A) . Because an aminopeptidase on the cell surface rapidly degrades TRAP, we repeated this experiment in the presence of amastatin (50 M), an aminopeptidase inhibitor. When hydrolysis of the NH 2 -terminal Ser of TRAP was blocked by amastatin, as little as 3 M TRAP potentiated the BK response. Increasing amounts of TRAP augmented B 2 R phosphorylation by BK (1 M); maximum phosphorylation (192% of control) was obtained with 30 -100 M TRAP in the absence of the aminopeptidase inhibitor. When 50 M amastatin was added to the reaction mixture, the effect of TRAP resembled that of thrombin (Figs. 5B and 6B ). TRAP potentiation of BK-induced B 2 R phosphorylation reached a maximum (232%) between 3 and 10 M concentration of the peptide, and higher concentrations decreased it (Fig. 6B) . 
DISCUSSION
We found that activation of PAR1 by either thrombin or the hexapeptide TRAP potentiates BK B 2 R agonists to enhance release of [ 3 H]AA. AA is the precursor of prostaglandins, such as prostacyclin, a coronary vasodilator, and prostaglandin E 2 , which prevents platelet aggregation. It is also a precursor of thromboxane (8, 35) . Although thrombin releases AA from many cell types, we used CHO cells in most of our experiments because they express native PAR1. Thrombin or TRAP released relatively small amounts of AA above baseline, but these agents both potentiated B 2 R agonists. In experiments repeated all together 35-40 times with human plasma kallikrein (10 nM) or BK (1 nM), we found that thrombin and TRAP consistently doubled AA release by these agonists. We obtained qualitatively similar results in experiments with human arterial endothelial cells that constitutively express both PAR1 and B 2 Rs.
Besides BK, we also tested human plasma kallikrein because kallikreins affect B 2 R differently than BK. It is clear that kallikrein action at the B 2 R does not depend on release of a kinin (19, 20) . As with BK, stimulation of the B 2 R by kallikrein was blocked by HOE-140, and both prokallikrein and inhibited kallikrein were inactive. Kallikrein and BK both desensitized the R, but there was no cross-desensitization. [ 3 H]AA release by BK was reduced 40% by addition of carboxypeptidase M, which removes Arg 9 . Carboxypeptidase M did not influence R activation by kallikreins and other proteases. Site-directed mutagenesis of the Arg 169 residue of the B 2 R further emphasized differences in the mechanisms of activation by the proteases and BK. The mutation decreased R activation by BK but not by kallikrein. In addition, our study shows that B 2 R activation by BK depends, at least in part, on Ca 2ϩ -independent PLA 2 activation while activation by kallikrein does not.
Potentiation at the B 2 R is not simply due to direct activation of PAR1 by the protease action of kallikrein, because we obtained similar results with the peptide agonist BK. We further ruled out a proteolytic action of thrombin at the B 2 R because TRAP, a specific agonist of PAR1, potentiated both BK and kallikrein. DFP-inhibited thrombin (inactive on PAR1) failed to enhance B 2 R activation by agonists. A scrambled peptide sequence of TRAP was equally inactive, indicating that the potentiation mechanism is initiated and mediated through activation of PAR1. TRAP did not affect substrate hydrolysis by kallikrein (not shown).
Lipid rafts are believed to be essential for BK B 2 R and epidermal growth factor R crosstalk (23) , and MCD blocks this interaction by depleting cholesterol, which disrupts complex formation. We found that 5 mM MCD failed to modify thrombin-induced potentiation in CHO/B 2 -transfected cells. Thus it seems unlikely that the potentiation phenomenon depends on PAR1/B 2 R dimer formation, even though B 2 Rs can form heterodimers with angiotensin-converting enzyme (ACE; Z. Chen and E. G. Erdös, unpublished observations and Ref. 28 ). In addition, because of the discrepancy in the ratio of PAR1 to B 2 expression in CHO/B 2 -transfected cells, potentiation cannot be due simply to colocalization; it is presumably a consequence of enhanced signal transduction.
In a comparable system, thrombin first activates G␣ q /PKC␣ and the G␣ 12/13 /Rho pathways to mobilize [Ca 2ϩ ] i in endothelial cells (21, 31 (29) . Now we find that low concentrations of thrombin (10 -30 nM) or TRAP (30 -100 M without addition of the aminopeptidase inhibitor amastatin and 1-10 M with amastatin) elevate BK B 2 R activity and increase phosphorylation of the R. Higher amounts of enzyme or peptide reversed the process and inhibited BK-initiated phosphorylation. Blocking of these effects by the IP 3 R inhibitor 2-APB and by the PKC␣ inhibitor Gö-6976 can be explained by coactivation of G␣ 12/13 and G␣ q /PKC␣ pathways by thrombin and the subsequent [Ca 2ϩ ] i mobilization that modulates B 2 R phosphorylation and activity. Increased phosphorylation is not likely due to increased expression of B 2 R, because we found no concomitant increase in B 2 -GFP total protein with the increase in R phosphorylation (Fig. 5) . In addition, inhibitors would unlikely alter protein synthesis and receptor expression during the brief time course of our experiments, but only modify activity. Additional controls where we measured [ 3 H]BK binding to the cell membrane indicated no modification by thrombin (data not shown). Figure 7 provides a scheme that summarizes pathways potentially involved in the interaction of PAR1 and B 2 R agonists.
We conclude that PAR1 R activation enhances the effects of BK B 2 R agonists in signal transduction, which then results in augmented release of AA. Because AA is a precursor of several vasoactive mediators, regulation of these pathways influences many diverse physiological functions. The cooperativity between the two Rs that we described for signal transduction pathways involved in AA release may underlie the cardioprotective nature of kinins in vivo.
